

Table III. Risk contributed to HCC development in univariate logistic model.

Items	<i>p</i> -value	Odds ratio	95% Confidence interval
Age	0.367	1.024	0.973–1.078
Gender (female)	0.167	0.592	0.282–1.246
BMI	0.997	1.000	0.879–1.138
Smoking habit	0.662	1.184	0.556–2.520
Albumin	0.356	0.862	0.629–1.182
Platelet counts	0.334	0.949	0.853–1.055
AFP	0.067	1.009	0.999–1.020
SNMC	0.101	1.864	0.886–3.922
UDCA	0.275	1.515	0.719–3.191
Sho-saiko-to	0.855	1.082	0.466–2.511
Juzen-taiho-to	0.913	0.921	0.210–4.047
Intermittently high ALAT (reference: continuously low ALAT)	0.325	1.536	0.654–3.609
Continuously high ALAT (reference: continuously low ALAT)	0.002	5.120	1.816–14.433

Abbreviations: HCC = hepatocellular carcinoma; BMI = body mass index; AFP = α -fetoprotein; SNMC = stronger-neo-minophagen C; UDCA = ursodeoxycholic acid; ALAT = alanine aminotransferase.

Table IV. Risk contributed to HCC development in a multivariate logistic model.

Items	<i>p</i> -value	Odds ratio	95% Confidence interval
Gender (female)	0.310	0.664	0.301–1.464
AFP	0.210	1.007	0.996–1.017
SNMC	0.501	1.327	0.581–3.029
Intermittently high ALAT (reference: continuously low ALAT)	0.506	1.354	0.554–3.307
Continuously high ALAT (reference: continuously low ALAT)	0.013	3.931	1.336–11.565

Abbreviations: HCC = hepatocellular carcinoma; AFP = α -fetoprotein; SNMC = stronger neo-minophagen C; ALAT = alanine aminotransferase.

development of HCC as the high AFP levels in the study by Oka et al. [29]. The odds ratio increased to 5.1-fold in patients with continuously high serum ALAT levels for the 3 years after diagnosis as compared with patients with continuously low ALAT levels for those years. In contrast, the odds ratio in patients with intermittently high ALAT levels was only 1.5-fold that of patients with low ALAT levels. Moreover, multivariate analysis confirmed that the ALAT group was independently associated with the development of HCC. Furthermore, the difference in cumulative incidence of HCC is more marked in the early period of follow-up than in the late period, suggesting the late occurrence of HCC in patients with continuously low ALAT levels for the 3 years following diagnosis of LC.

Recently many studies have demonstrated the close association between ALAT levels and the development of HCC. Ishiguro et al. [30] demonstrated that serum ALAT concentration was dependently associated with an increased risk of HCC in both virus-positive and virus-negative participants in a large population-based cohort study in Japan. Kurokawa et al. [31] studied the long-term effects of INF- α -2b plus ribavirin therapy on the incidence of HCC in patients with chronic hepatitis C and found that the cumulative incidence of HCC was significantly lower in patients who had average serum ALAT levels of <40 IU/L than in those who showed average serum ALAT levels of \geq 40 IU/L after combination therapy. Moreover, Kumada et al. [32,33] surveyed the risk factors involved in the development of HCC in patients with chronic

HCV infection who had normal ALAT levels (<40 IU/L) over 10 years, and found that a slightly high ALAT level (>20 IU/L) was closely associated with the development of hepatocarcinogenesis.

The next issue is why the risk of developing HCC was increased so markedly in the continuously high ALAT group, as demonstrated in this study. It is likely that genetic alterations accumulate rapidly as inflammation persists and that the multistep process of carcinogenesis or promotion of tumor growth progresses more rapidly in patients with continuously high ALAT levels. In this respect, Ferenc et al. [34] demonstrated significant differences in the p53 expression between mildly, moderately, and severely inflamed biopsy samples in ulcerative colitis. 8-hydroxy-2'-deoxyguanosine (8-OHdG) is a pro-mutagenic DNA lesion produced by oxygen (hydroxy) radicals [35,36], and is known to be a parameter of genetic risk for hepatocarcinogenesis [37]. Furthermore, 8-OHdG was demonstrated to be involved in the initiation of rat liver hepatocarcinogenesis by low doses of N-nitrosodiethylamine (DEN) [38].

Shimoda et al. [39] examined the levels of 8-OHdG in patients with chronic hepatitis, liver cirrhosis, and HCC and found that the OHdG level in liver affected by chronic hepatitis was significantly higher than that in normal liver, and that the OHdG level in liver affected by cirrhosis also tended to be higher than that in normal liver. They also found a significant correlation between the OHdG content in non-cancerous liver tissue and individual serum ALAT levels, and concluded that chronic inflammation in the liver might produce oxidative DNA damage, which would increase the risk of genomic alterations causing hepatocarcinogenesis. If high-grade inflammation persists in the liver for many years, as in the continuously high ALAT group of patients in our study, the level of 8-OHdG might be high throughout the cirrhotic liver, resulting in the development of HCC.

Nowadays, patients with chronic hepatitis C in all countries are generally treated with IFN, and more than 50% of patients become HCV-RNA negative following PEG-IFN plus ribavirin therapy, but unfortunately, the IFN therapy is not effective in about 70% of patients with HCV-associated liver cirrhosis. Moreover, patients with HCV-associated cirrhosis carry a high risk of HCC, and in Japan, HCC actually develops in about 7% of those patients every year [40]. A strategy for preventing HCC development other than IFN therapy is therefore urgently needed for those patients.

In conclusion, we demonstrated that if the serum ALAT level was high (≥ 80 IU) for 3 successive years following the diagnosis of LC, then the risk of subsequently developing HCC increased markedly as compared with the continuously low ALAT group

in Child A HCV-LC patients. Multivariate analysis confirmed that the ALAT group of LC was independently associated with HCC development. Thus, continuously high ALAT levels for 3 years following the diagnosis of LC (Child Stage A) can be highly predictive of the development of HCC. However, prospective trials using therapeutic approaches to decrease ALAT levels are necessary to confirm a positive impact of ALAT reduction on the incidence of HCC in patients with HCV-LC. The present study suggests that serum ALAT levels in HCV-LC patients must be lowered to below 80 IU by anti-inflammatory drugs as soon as a diagnosis of LC is confirmed.

Acknowledgements

The present work was supported by the Fund for Cancer Research from the Ministry of Welfare of Japan, the Mitsui Life Social Welfare Foundation, the Viral Hepatitis Research Foundation of Japan, and the Kanagawa Health Foundation.

Declaration of interests: No conflict of interests existed in our present work.

References

- [1] Slaga TJ, Scribner JD. Inhibition of tumor initiation and promotion by anti-inflammatory agents. *J Natl Cancer Inst* 1973;51:1723-25.
- [2] Cameron R, Lee G, Farber E. Chemical mitogens as effective alternatives to partial hepatectomy in the new model for the sequential analysis of hepatocarcinogenesis. *Proc Am Assoc Cancer Res* 1978;19:56.
- [3] Marks F, Bertsch S, Grimm W, Schweizer J. Hyperplastic transformation and tumor promotion in mouse epidermis: possible consequences of disturbances of endogenous mechanism controlling proliferation and differentiation. In: Slaga TJ, Sivak A, Boutwell RK, editors. *Carcinogenesis*, vol. 2. New York: Raven Press; 1978. pp 97-116.
- [4] Argyris TS. Tumor promotion by damage-induced epidermal hyperplasia in the skin of mice. *Proc Am Assoc Cancer Res* 1979;20:4.
- [5] Vasiliev JM, Moizhess TG. Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body. *Int J Cancer* 1982;30:525-9.
- [6] Hamada J, Takeichi N, Okuda F, Ren J, Li X, Hosokawa M, et al. Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates. *Jpn J Cancer Res* 1992;83:483-90.
- [7] Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991;325:1170-1.
- [8] Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 2001;345:784-9.

- [9] Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. *Gut* 1990;31:800-6.
- [10] Belamaric J. Intrahepatic bile duct carcinoma and *C. sinensis* infection in Hong Kong. *Cancer* 1973;31:468-73.
- [11] Sugihara S, Kojiro M. Pathology of cholangiocarcinoma. In: Okuda K, Ishak KG, editors. *Neoplasms of the Liver*. Tokyo: Springer; 1987. pp 143-58.
- [12] Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 2000;132:517-24.
- [13] Okita M, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. *Oncology* 2002;62Suppl:24-8.
- [14] Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. *Cancer* 1999;86:589-95.
- [15] Child CG III, Turcotte JG. Surgery and portal hypertension. Dunphy JE, editor. *The liver and portal hypertension*. Philadelphia: WB Saunders; 1964. p 50.
- [16] Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. *Science* 1982;218:474-6.
- [17] Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. *Cancer* 1994;73:1149-54.
- [18] Tarao K, Shimizu A, Ohkawa S, Tamai S. Prediction of the development of hepatocellular carcinoma from HCV-associated liver cirrhosis. *J Jpn Soc Int Med* 1995;84:1985-91.
- [19] Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. *Radiology* 1985;154:10-24.
- [20] Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis double blind trial. *Asian Med J* 1983;26:423-38.
- [21] Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. *Gastroenterol Jpn* 1989;24:715-9.
- [22] Hino K, Miyakawa H, Takahashi J, Kumada H, Ikeda K, Yoshida A, et al. Histological improvement in inflammation in chronic hepatitis by administration of stronger-seominophargen C (SNMC) [in Japanese]. *Kan-Tan-Sui* 1986;13:797-807.
- [23] Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. *J Hepatol* 1993;19:459-64.
- [24] Tarao K, Tamai S, Ohkawa S, Miyakawa K, Aoki H, Takashimizu S, et al. The effects of combined drug therapy on the serum alanine aminotransferase level in HCV-associated liver cirrhosis [in Japanese]. *Rinsho-to Kenkyu* 1998;75:1858-67.
- [25] Hosmer DW, Lemeshow S. *Applied logistic regression*. Chichester, UK: John Wiley; 1989.
- [26] Gooley TA, Leisenring W, Cyowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks; new presentation of old estimations. *Stat Med* 1999;18:695-706.
- [27] Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. *J Am Stat Assoc* 1958;53:457-81.
- [28] Mahmood S, Togawa K, Kawanaka M, Niiyama G, Yamada G. An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy. *Cancer Inform* 2008;6:381-7.
- [29] Oka H, Tamori A, Kuroki T, Kobayashi M, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology* 1994;19:61-6.
- [30] Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. *Eur J Cancer Prev* 2009;18:26-32.
- [31] Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushiji T, Kurashige N, et al. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. *Hepatol Res* 2009;39:432-8.
- [32] Kumada T, Toyoda H, Kiriya S, Sone Y, Tanikawa M, Kanamori A, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. *J Hepatol* 2009;50:729-35.
- [33] Kumada T, Toyoda H, Kiriya S, Sone Y, Tanikawa M, Hisanaga Y, et al. Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase. *J Med Virol* 2009;81:446-51.
- [34] Ferenc S, Bela M, Tamas Z, Lajos B, Zsolt T. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. *Dis Col Rect* 2005;48:775-86.
- [35] Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. *Nucleic Acid Res* 1984;12:2137-45.
- [36] Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. *Nature (Lond)* 1991;349:431-4.
- [37] Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, et al. Effect of sho-saiko-to on hepatocarcinogenesis and 8-hydroxy 2' deoxyguanosine formation. *Hepatology* 2002;35:1125-33.
- [38] Nakae D, Kobayashi Y, Akai H, Andoh N, Satoh H, Ohashi K, et al. Involvement of 8-hydroxyguanosine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. *Cancer Res* 1997;57:1281-7.
- [39] Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. *Cancer Res* 1994;54:3171-2.
- [40] Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. *Hepatology* 1999;29:1124-30.

A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer

Junji Furuse · Takuji Okusaka · Shinichi Ohkawa ·
Michitaka Nagase · Akihiro Funakoshi · Narikazu Boku ·
Kenji Yamao · Taketo Yamaguchi · Toshiya Sato

Received: 27 December 2008 / Accepted: 13 April 2009 / Published online: 29 April 2009
© Springer-Verlag 2009

Abstract

Purpose The purpose of this study was to clarify the safety and efficacy of combination chemotherapy of uracil-tegafur (UFT) and doxorubicin (UFD regimen), and to identify the prognostic factors in patients with unresectable advanced biliary tract cancer who received systemic chemotherapy.

Methods Patients with histologically or cytologically confirmed, measurable biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, who were not suitable candidates for surgery, were eligible for the study. Patients received oral UFT at 300 mg/m² per day divided into two doses on days 1–14 and intravenous doxorubicin at 30 mg/m² on day 1. This cycle was repeated every 21 days. The

relationship between the patient characteristics and the prognosis was examined. Univariate and multivariate analyses were conducted to identify the prognostic factors associated with survival.

Results Sixty-one patients from 12 institutions were enrolled in the late phase II study between April 2005 and March 2006. Of the 61 patients, 4 patients had partial responses, for an objective response rate of 6.6% (95% CI: 1.8–15.9%); 28 patients had stable disease, 27 had progressive diseases, and 2 patients were not evaluated. The median progression-free survival was 1.6 months, and the overall median survival time was 6.5 months. In the 85 patients who received this UFD chemotherapy in previous and late phase II studies, multivariate analysis revealed the ECOG performance status 1 ($P = 0.001$), gallbladder as the

J. Furuse
Division of Hepatobiliary and Pancreatic Oncology,
National Cancer Center Hospital East, Kashiwa, Japan

T. Okusaka
Hepatobiliary and Pancreatic Oncology Division,
National Cancer Center Hospital, Tokyo, Japan

S. Ohkawa
Division of Hepatobiliary and Pancreatic Medical Oncology,
Kanagawa Cancer Center, Yokohama, Japan

M. Nagase
Department of Imaging Diagnosis,
Tochigi Cancer Center, Utsunomiya, Japan

A. Funakoshi
Department of Gastroenterology,
National Kyushu Cancer Center, Fukuoka, Japan

N. Boku
Division of Gastrointestinal Oncology,
Shizuoka Cancer Center, Suntou-gun, Shizuoka, Japan

K. Yamao
Department of Gastroenterology,
Aichi Cancer Center, Nagoya, Japan

T. Yamaguchi
Department of Medicine and Clinical Oncology,
Graduate School of Medicine, Chiba University, Chiba, Japan

T. Sato
Department of Biostatistics,
Kyoto University School of Public Health, Kyoto, Japan

J. Furuse (✉)
Department of Internal Medicine, Medical Oncology,
Kyorin University School of Medicine, 6-20-2, Shinkawa,
Mitaka, Tokyo 181-8611, Japan
e-mail: jfuruse@ks.kyorin-u.ac.jp

primary cancer site ($P = 0.014$), T-factor 4 of the TNM classification ($P = 0.035$), and elevated serum lactate dehydrogenase levels ($P = 0.043$) as being associated with a significantly shorter survival.

Conclusions Combination chemotherapy of UFT and doxorubicin had minimum activity against advanced biliary tract cancer. Performance status was identified as the most important prognostic factor in patients who received systemic chemotherapy.

Keywords Biliary tract cancer · Systemic chemotherapy · Uracil-tegafur · Doxorubicin · Phase II study · Prognostic factor

Introduction

Biliary tract cancer consists of cholangiocarcinoma (CC), gallbladder cancer (GBC), and ampullary cancer (AC) [1]; intrahepatic cholangiocarcinoma is often included in clinical trials for biliary tract cancer. Each type of cancer has characteristic features, and the treatment strategy and prognosis are different. This heterogeneity has made it difficult to conduct and evaluate chemotherapy for biliary tract cancer. Biliary tract cancer is relatively uncommon in western countries, but it is a common cause of cancer-related death in Asia. In Japan, the mortality is estimated to be 16,000 deaths annually [2]. While surgery currently remains the only potentially curative treatment, most patients are found to have an unresectable advanced stage of disease. Although patients with unresectable disease receive various palliative treatments, including systemic chemotherapy, the prognosis remains extremely poor.

A previous report showed improved survival in patients with biliary tract cancer treated with 5-fluorouracil (5-FU)-based chemotherapy compared to the best supportive care [3]. Efforts have been made to develop promising regimens for biliary tract cancer using clinical trials of systemic chemotherapy [4]. In various reports on chemotherapy for biliary tract cancer, fluoropyrimidines have been considered as the basis of chemotherapy [5–7]. Furthermore, cisplatin or anthracycline antitumor antibiotic agents such as doxorubicin and epirubicin have been used as combination chemotherapy with 5-FU [8–10]. Recently, clinical trials of gemcitabine show moderate activity against biliary tract cancers, and gemcitabine-based regimens have been investigated [11–22]. However, no standard chemotherapy has currently been identified that can clearly prolong survival.

In Japan, until 2006, only three anticancer agents—uracil-tegafur (UFT), doxorubicin, and cytarabine—had been approved by the Ministry of Health, Labour, and Welfare for biliary tract cancer. Uracil-tegafur is an orally administered drug that is a combination of uracil and tegafur in a

4:1 molar concentration ratio. Tegafur is a 5-FU prodrug that is hydroxylated and converted to 5-FU by hepatic microsomal enzymes. Uracil prevents degradation of 5-FU by inhibiting dihydropyrimidine dehydrogenase, which leads to an increased level of 5-FU in plasma and tumor tissues [23, 24]. Doxorubicin is an anthracycline antibiotic that induces various biologic effects and has one of the widest spectra of antitumor activity against lymphomas, leukemias, soft tissue sarcomas, and a variety of carcinomas. Because, UFT + doxorubicin is the only doublet regimen currently covered by health insurance in Japan, we investigated the combination of UFT and doxorubicin (the UFD regimen) in patients with unresectable advanced biliary tract cancer as an early phase II study in 2004. In that study, the UFD showed modest activity; the response rate was 12.5%, the median progression-free survival (PFS) was 2.5 months, and the median overall survival (OS) was 7.6 months [25]. To examine the safety and efficacy in a larger number of patients, a multicenter late phase II study was conducted in a Japanese chemotherapy study group for biliary tract and pancreatic cancers. The objectives of the study were to evaluate response rate, toxicity, PFS, and OS. As an additional exploratory analysis, we examined the prognostic factors in patients with unresectable biliary tract cancer who had received the UFD regimen in the early and current phase II studies.

Patients and methods

Patient eligibility

The eligibility criteria for enrollment in this late phase II study were: (1) histologically or cytologically confirmed biliary tract cancer consisting of intrahepatic CC (ICC), extrahepatic CC (ECC), GBC, or AC; (2) measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI); (3) unresectable disease; (4) no prior chemotherapy; (5) age ≥ 20 years, with a set upper limit of 74 years according to another Japanese trials of gemcitabine and S-1 [13, 26]; (6) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2; (7) adequate bone marrow function (leukocyte count $\geq 4,000$ cells/mm³, platelet count $\geq 100,000$ cells/mm³, and hemoglobin ≥ 9.0 g/dL), renal function (serum creatinine concentration \leq upper limit of normal range), and hepatic function [serum bilirubin level ≤ 2.0 mg/dL, serum albumin level ≥ 3.0 g/dL, and serum aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 times the upper limit of normal range]; (8) life expectancy ≥ 8 weeks; and (9) written informed consent from the patient. Percutaneous biliary drainage was performed in patients with obstructive jaundice and these patients were

required to have serum bilirubin levels of ≤ 3.0 mg/dL, and serum AST and ALT levels ≤ 5 times the upper limit of normal before enrollment. Exclusion criteria were: serious complications such as active infection, active gastrointestinal ulcer, cardiac disease, or renal disease; central nervous system metastasis; marked pleural effusion or ascites; symptomatic interstitial pneumonitis; and pregnancy or lactation for women. This study was approved by the local institutional review boards at all participating centers.

In addition, prognostic factors were analyzed in patients treated with the UFD regimen in the earlier and current phase II studies. The eligibility criteria for enrollment in the previous study were the same as those mentioned above for the current study, except that the upper age limit of 74 years for enrollment was not set.

Treatment methods

Uracil-tegafur was administered orally at a dose of 300 mg/m² per day (400 mg/day in patients with body surface < 1.50 m² and 500 mg/body per day in patients with body surface ≥ 1.50 m²) divided into two dosages, for 14 consecutive days followed by 1 week of rest. Doxorubicin was given as a 10-min intravenous infusion on day 1 of each cycle at a dose of 30 mg/m². This cycle was repeated every 21 days provided that patients had recovered sufficiently from the drug-related side effects.

Patients continued to receive additional courses of this regimen until a maximum of 15 courses, evidence of disease progression, or the appearance of unacceptable toxicity. When hematological toxicity greater than grade 3 or nonhematological toxicity greater than grade 2 was observed, treatment was delayed until the toxicity subsided to grade 1 or less. If the daily dose of UFT was considered to be intolerable, the dose was reduced by 100 mg/day (one capsule/day). In general, patients were treated as outpatients and admitted to the hospital only for management of toxicities and disease-related complications.

Assessment of response and toxicity

Physical examination, complete blood cell counts, serum chemistries, and urinalysis were performed at baseline and at least twice in 3 weeks after initiating treatment. Patients underwent dynamic CT or MRI to evaluate response at 4–6-week intervals after the start of treatment. Computed tomography or MRI was performed by obtaining contiguous transverse sections using the helical scanning method at a section thickness of 5 mm. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors [27]. Objective responses were confirmed by a second evaluation performed at least 4 weeks later. Toxicity was graded according to the

National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.

Study designs

The primary end point of this study was the overall response rate and the secondary endpoints were adverse events, OS, and PFS. In this study, the threshold response rate was defined as 5%, the expected response rate was set as 15%, and a sample size of 40 would ensure that there was a 74% power at a one-sided significance level of 5% in the late phase II study. The accrual period was set at 1 year and follow-up period was set at 1 year. When 40 patients were enrolled, the enrollment was extended until the end of the accrual time to improve the statistical power.

Factors analyzed

Twenty-three clinical variables were chosen at the time of study enrollment for the univariate and multivariate analyses. Each variable was divided into two categories as follows: age (< 64 or ≥ 64 years), sex (male or female), PS (0 or 1), pretreatment (surgery or no treatment), biliary drainage (yes or no), diagnosis (GBC or non-GBC including ICC, ECC, and AC), white blood cell count ($< 8,000$ or $\geq 8,000$ /mL), hemoglobin level (< 11.0 or ≥ 11.0 g/dL), platelet count ($< 150,000$ or $\geq 150,000$ /mL), serum total bilirubin level (< 2.0 or ≥ 2.0 mg/dL), serum albumin level (< 3.5 or ≥ 3.5 g/dL), serum lactate dehydrogenase (LDH) level (< 300 or ≥ 300 IU/L), serum AST and ALT levels (< 40 or ≥ 40 IU/L), serum alkaline phosphatase (< 400 or ≥ 400 IU/L), size of maximum targeted tumor (< 60 mm or ≥ 60 mm), T-factor of TNM classification (Tx-3 or T4) [1], extent of disease (locally advanced and local recurrence after surgery, or metastatic), liver metastasis (presence or absence), ascites or peritoneal dissemination (presence or absence), lymph node metastasis (presence or absence), serum carcinoembryonic antigen (CEA) level (< 10 or ≥ 10 ng/mL), and serum carbohydrate antigen 19-9 (CA 19-9) level ($< 1,000$ or $\geq 1,000$ U/mL). The size of the primary tumor was measured by enhanced CT. Peritoneal dissemination was defined as recognition of peritoneal nodules in CT scans or accumulation of ascites.

Statistical analysis

Progression-free survival was calculated from the first day of treatment until evidence of tumor progression, clinical progression, or death due to any cause. Overall survival was calculated from the first day of treatment until death due to any cause. Survival data were analyzed using the Kaplan–Meier method. The tumor response, toxicity, and survival were evaluated on an intention-to-treat basis.

As an additional and unplanned analysis, the Cox proportional hazards model was used to evaluate prognostic variables associated to survival in patients with unresectable biliary tract cancer who received the UFD regimen in two phase II studies. Forward and backward stepwise regression procedures based on the partial likelihood ratio were used to determine the major independent predictors of survival. Statistical analyses were performed using the SPSS II 11.0 J software package for Windows (SPSS Japan, Tokyo, Japan). The statistical significance of differences between the survival curves was determined using the log-rank test. Two-sided *P*-values of less than 0.05 were considered significant.

Results

Patient characteristics

A total of 61 patients were enrolled between April 2005 and March 2006 in the late phase II study. Patient characteristics are shown in Table 1. The 61 patients received 244 cycles of the UFD regimen. The median number of cycles administered per patient was two (range 1–16 cycles). All patients discontinued this treatment: 50 experienced disease progression, six patients refused further treatment, two patients experienced serious adverse events of disseminated intravascular coagulation (DIC), or thrombocytopenia, and in three patients doxorubicin reached the upper limit dose. After abandoning the UFD treatment, 28 (45.9%) patients received second-line treatment; 30 patients had systemic chemotherapy with gemcitabine in 18 patients, UFT in 7, doxorubicin in 1; 1 patient had chemoradiotherapy and the other had immunotherapy. Three patients were unknown because of moving to another hospital. The remaining 30 (49.2%) patients received only best supportive care after the UFD treatment.

Tumor response

Partial response was achieved in 4 of the 61 patients (2 with GBC and 2 with ECC), but no complete response was observed. Overall response rate was thus 6.6% [95% confidence interval (CI), 1.8–15.9%], and 8.7% (95% CI, 2.6–14.7%) in 85 patients including 24 patients in the early phase II study. Stable disease (SD) was noted in 28 (45.9%) of the 61 patients and progressive disease (PD) was noted in 27 patients (44.3%). The remaining two patients who refused the treatment before the evaluation were not evaluated for response.

Toxicity

Toxicities of the 61 patients are shown in Table 2. During treatment, the most common toxicities were gastrointestinal

Table 1 Patient characteristics

	Current phase II study	Previous phase II study
<i>N</i>	61	24
Sex		
Male	27 (44%)	13 (54%)
Female	34 (56%)	11 (46%)
Median age (range)	65 (46–74) years	63 (46–75) years
ECOG performance status		
0	45 (74%)	16 (67%)
1	16 (26%)	8 (33%)
Location of primary tumor		
Gallbladder cancer	29 (48%)	13 (54%)
Intrahepatic cholangiocarcinoma	18 (30%)	10 (42%)
Extrahepatic cholangiocarcinoma	11 (18%)	1 (4%)
Ampullary cancer	3 (5%)	0 (0%)
Extent of disease		
Locally advanced or local recurrence after surgery	10 (16%)	5 (21%)
Metastatic	51 (84%)	19 (79%)
Metastatic sites		
Lymph node	43 (70%)	15 (63%)
Liver	35 (57%)	16 (67%)
Lung	6 (10%)	4 (17%)
Peritoneum	7 (11%)	1 (4%)
Bone	2 (3%)	1 (4%)
Adrenal gland	1 (2%)	0 (0)
Pleura	1 (2%)	0 (0)
Pretreatment		
No	44 (72%)	18 (75%)
Surgery	17 (28%)	6 (25%)

effects such as anorexia in 38 patients (62.3%) and nausea in 35 patients (57.4%). Other major symptoms were fatigue in 35 patients (57.4%), hematological toxicities of anemia in 23 patients (32.8%), and leukopenia in 17 patients (27.9%). Grade 3 or 4 toxicity was observed in 4 of the 61 patients (6.6%), with anorexia, nausea, fatigue, DIC, and/or hematological toxicities. There were no treatment-related deaths during the study.

Survival

Disease progression was finally observed in 57 of the 61 patients. The progression pattern was progression of target lesions in 24 patients (42.1%), developments of new lesions in 10 (17.5%), both of these in 11 (19.3%), symptomatic deterioration without objective evidence of disease progression in 9 (15.8%), progression of non-target lesion and new

Table 2 Toxicity (*n* = 61)

Toxicity	Grade 1–4	Grade 3	Grade 4
Hematological			
Leukopenia	17 (28%)	2 (3%)	0 (0)
Neutropenia	14 (23%)	0 (0%)	0 (0)
Anemia	23 (38%)	1 (2%)	2 (3%)
Thrombocytopenia	9 (15%)	2 (3%)	0 (0)
Non-hematological			
Anorexia	38 (62%)	5 (8%)	1 (2%)
Nausea	35 (57%)	2 (3%)	0 (0)
Fatigue	35 (57%)	3 (5%)	1 (2%)
Alopecia	19 (31%)	0 (0)	0 (0)
Vomiting	13 (21%)	0 (0)	0 (0)
Abdominal pain	12 (20%)	0 (0)	0 (0)
Mucositis	10 (16%)	0 (0)	0 (0)
Fever	7 (11%)	0 (0)	0 (0)
Diarrhea	5 (8%)	0 (0)	0 (0)
Transaminase elevation	4 (7%)	0 (0)	0 (0)
Rash	4 (7%)	0 (0)	0 (0)
Pigmentation	3 (5%)	0 (0)	0 (0)
Arrhythmia	2 (3%)	0 (0)	0 (0)
Taste disturbance	1 (2%)	0 (0)	0 (0)
Edema	1 (2%)	0 (0)	0 (0)
Constipation	1 (2%)	0 (0)	0 (0)
Total bilirubin	1 (2%)	0 (0)	0 (0)
Sore throat	1 (2%)	0 (0)	0 (0)
Hand–foot skin reaction	1 (2%)	0 (0)	0 (0)
BW loss	1 (2%)	0 (0)	0 (0)
DIC	1 (2%)	1 (2%)	0 (0)

BW body weight, DIC disseminated intravascular coagulation

lesions in 3 (5.3%). Fifty of the 61 patients died: 49 patients died of cancer progression, and in the case of the other patient, the death was reported and the cause was unknown. The median PFS was 1.6 months in the 61 patients. The median OS time was 6.5 months and the 1-year survival rate was 30.0%.

Univariate and multivariate analyses

Among the 23 variables in 85 patients who received the UFD chemotherapy in the early and late phase II studies, six variables were identified as being significantly associated with shorter survival time: PS of 1, diagnosis of GBC, serum CA 19–9 level of >1,000 U/mL, T-factor of 4, serum LDH level of ≥300 IU/L, and serum total bilirubin level of ≥2.0 mg/dL by univariate analysis. The median PFS was 2.2 months in the 85 patients (Fig. 1). The median OS time was 6.6 months and the 1-year survival rate was 28.2% (Fig. 2). The median OS of patients




Fig. 1 Progression-free survival of all 85 patients. The median progression-free survival was 2.2 months and the 6-month survival rate was 14.3%




Fig. 2 Overall survival of all 85 patients. The median overall survival was 6.6 months and the 1-year survival rate was 28.2%

with PS 0 was 8.2 months and that of patients with PS 1 was 4.3 months. There was a statistically significant difference in the survival curves between the two groups (*P* < 0.0001). Figure 3 shows survival curves for patients with non-GBC of ICC, ECC, or AC and for patients with GBC. The median OS of the patients with GBC was 5.4 months and that of the patients without GBC was 8.4 months. There was a statistically significant difference in the survival curves between the two groups (*P* = 0.0019). On the other hand, there was no statistically significant difference in the survival among patients with ICC, ECC, or AC.

Multivariate regression analysis was conducted for the six variables found to have prognostic significance in the univariate analysis. The four factors of PS, disease site, T-factor, and serum LDH were identified as independent prognostic factors (Table 3).




Fig. 3 Survival curves of patients with gallbladder cancer (a, $n = 42$) and with non-gallbladder cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or ampullary cancer (b, $n = 43$) ($P = 0.0019$)

Table 3 Multivariate analysis of prognostic factors in patients with unresectable biliary tract cancer

Variables	<i>N</i>	Median OS (mo)	Hazard ratio	95%CI	<i>P</i> -value
ECOG PS					
0	61	8.2	1		0.001
1	1	4.3	2.52	1.44–4.42	
Disease site					
ICC/ECC/AV	43	8.4	1		0.014
GB	42	5.4	1.88	1.14–3.12	
T-factor					
T1–3	62	8.1	1		0.035
T4	23	5.0	1.93	1.05–3.56	
LDH					
<300	67	8.1	1		0.043
≥300	18	4.8	1.85	1.02–3.35	
CA19-9					
<1,000	59	8.1	1		0.067
≥1,000	26	5.2	1.73	0.96–3.11	
T-Bil					
<2.0	77	6.6	1		0.27
>2.0	8	5.2	1.85	0.70–3.49	

OS overall survival, CI confidence interval, PS performance status, ICC intrahepatic cholangiocarcinoma, ECC extrahepatic cholangiocarcinoma, GB gallbladder cancer, AV ampullary cancer, LDH lactate dehydrogenase, CA19-9 carbohydrate antigen 19-9, T-Bil serum total bilirubin

Discussion

Chemotherapy is generally indicated in patients with unresectable advanced cancer and patients with recurrence after resection. However, no standard chemotherapy for biliary

tract cancer has yet been established, because only few randomized controlled trials with large numbers of patients have been conducted till date. Since only UFT and doxorubicin had been approved for biliary tract cancer for more than 20 years in Japan, the efficacy and safety of combinations of UFT and doxorubicin were examined in two phase II studies. The expected response rate was set as 15%, because biliary tract cancer was considered to be chemoresistant. The overall response rate in the two phase II studies was 8.7% (95% CI, 2.6–14.7%). The upper limit of the 95% confidence interval did not reach 15%, and the combination of UFT and doxorubicin was decided to have minimum activity against biliary tract cancer.

Response rate is sometimes not correlated with OS. Eckel et al. reported a pooled analysis of clinical trials in biliary tract cancer [28]. Based on the analysis of 104 phase II studies comprising of 112 trial arms, there was a highly significant correlation between time to progression (TTP) and OS ($r = 0.73$, $P = 0.000$), but there was a significant weak correlation between response rate and OS ($r = 0.2$, $P = 0.043$). Furthermore, it was reported that the pooled tumor control rate was 57.3% (95% CI: 55.3–59.3%), the median TTP was 4.1 months, and the median OS was 8.2 months. In the current studies, the tumor control rate (CR + PR + SD) was 56.4% (95% CI: 44.1–66.1%), which was almost equal to the pooled TCR, but the median PFS and OS were inferior to those of the pooled analysis, only 2.2 months and 6.6 months, respectively. The TTP or PFS seems appropriate as a surrogate marker of OS compared to the TCR.

It is difficult to conduct clinical trials consisting of a large number of patients with biliary tract cancer, because complications such as obstructive jaundice or cholangitis make it difficult to recruit eligible patients. Therefore, most of the clinical trials of chemotherapy for biliary tract cancer consist of less than 50 patients. Owing to the lack of clinical trials with large patient numbers, few analyses of prognostic factors in patients with advanced biliary tract cancer who received chemotherapy have been conducted till date. In the current phase II studies, 85 patients who received the same regimen of chemotherapy were enrolled and the patient characteristics in the two studies were almost the same. Therefore, we tried to determine the prognostic factors with univariate and multivariate analyses. Although some limitations of these methods should be recognized, such as insufficient patient number to allow adequate statistical power to be obtained, four factors, namely, the PS, disease site, T-factor, and serum LDH were identified as independent prognostic factors; PS was the most important prognostic factor with a hazard ratio of 2.52 ($P = 0.001$).

It has been reported for the advanced stage of various cancers, including pancreatic cancer, that the survival differs significantly depending on the extent of disease, that

is, depending on whether the disease is locally advanced or metastatic. In the current study, the median OS of the patients with locally advanced cancer was longer than that of patients with metastatic disease (8.2 months vs. 5.8 months), although there was no statistically significant difference in survival between the two patient groups ($P = 0.18$). We believe that this could possibly be explained by the smaller number of patients with locally advanced disease ($n = 15$) compared to that with metastatic disease ($n = 70$).

Performance status is often mentioned as an important independent prognostic factor, in various cancers such as pancreatic cancer and hepatocellular carcinoma. The clinical practice guideline for the management of biliary tract cancer in Japan recommends that patients with a PS of two or more should not receive chemotherapy at the present time [29]. Since most clinical trials of chemotherapy for biliary tract cancer conducted till date have included patients with a PS of 2, the protocol of the current study also allowed the entry of patients with a PS of 2. However, only patients with a PS of 0 or 1 were actually enrolled. We investigated the prognostic factors to distinguish between PS 0 and 1, and found a statistically significant difference in survival between PS 0 and 1. The median OS in patients with a PS of 0 was 8.2 months and in patients with a PS of 1 was 4.3 months. Patients with a PS of 1 may be candidates for chemotherapy, but the survival is shorter than that in patients with a PS of 0.

The heterogeneity of biliary tract cancer is recognized to be one of the most important issues in considering prognosis of patients with biliary tract cancer. Regarding the primary site, the median OS in patients with gallbladder cancer was statistically significantly shorter than that in patients with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma or ampullary cancer in the current study ($P = 0.014$). Some other trials showed this tendency [16, 20] but some did not [11, 12, 26]. The reason for this discrepancy is not clear but the small number of patients in each trial may be one of the reasons. In a retrospective analysis of a large number of patients ($n = 179$) [30], the median OS was 8.44 months for intrahepatic cholangiocarcinoma, 10.15 months for extrahepatic cholangiocarcinoma, and 6.50 months for gallbladder cancer. There was a statistically significant difference between extrahepatic cholangiocarcinoma and gallbladder cancer ($P = 0.029$). In the current study, a multivariate analysis in patients with unresectable biliary tract cancer who received the same regimen revealed that the site of disease was one of the significant prognostic factors. Therefore, PS and tumor site of gallbladder cancer or non-gallbladder cancer should be considered in randomized clinical trials for unresectable biliary tract cancer.

No standard chemotherapy for biliary tract cancer has yet been established till date. In Japan, recently, two registration phase II studies of a single agent, gemcitabine and S-1, have been reported [13, 26]. Gemcitabine achieved a better response rate, PFS, and OS compared with the UFT or UFD regimens. Furthermore, S-1 also seems active. Both gemcitabine and S-1 were well tolerated. Based on these results, gemcitabine and S-1 were approved for the treatment of biliary tract cancer in June 2006 and August 2007, respectively.

In conclusion, combination chemotherapy with UFT and doxorubicin (the UFD regimen) was well tolerated but showed minimum activity against advanced biliary tract cancer. Further studies of gemcitabine, S-1, and other cytotoxic or molecular targeted agents are expected to lead to the establishment of a standard chemotherapy for biliary tract cancer.

Acknowledgments This study was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health, Labour, and Welfare of Japan.

References

1. Sobin LH, Wittekind CH (eds) (2002) TNM classification of malignant tumours. Liver, UICC, 6th edn. Wiley-Liss, New York, pp 82–83
2. National Cancer Center. Cancer statistics in Japan 2007. <http://www.fpcr.or.jp/publication/statistics.html>. Accessed 10 March, 2008
3. Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. *Ann Oncol* 7:593–600
4. Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. *Eur J Cancer* 34:977–986
5. Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. *Cancer* 54:965–969
6. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Rajman I et al (1996) Phase II trial of intravenous fluorouracil and subcutaneous interferon alpha-2b for biliary tract cancer. *J Clin Oncol* 14:2311–2315
7. Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. *J Clin Oncol* 2:1245–1248
8. Ellis PA, Norman A, Hill A et al (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. *Eur J Cancer* 31A:1594–1598
9. Morizane C, Okada S, Okusaka T, Ueno H, Saisho T (2003) Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. *Oncology* 64:475–476
10. Rao S, Cunningham D, Hawkins RE et al (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. *Br J Cancer* 92:1650–1654
11. Penz M, Kornek GV, Raderer M et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. *Ann Oncol* 12:183–186

12. Tsavaris N, Kosmas C, Gouveris P et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. *Invest New Drugs* 22:193–198
13. Okusaka T, Ishii H, Funakoshi A et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. *Cancer Chemother Pharmacol* 57:647–653
14. Hsu C, Shen YC, Yang CH et al (2004) Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. *Br J Cancer* 90:1715–1719
15. Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. *Cancer* 103:111–118
16. Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. *J Clin Oncol* 23:2332–2338
17. Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. *Cancer* 104:2753–2758
18. Doval DC, Sekhon JS, Gupta SK et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naïve, unresectable gall bladder cancer. *Br J Cancer* 90:1516–1520
19. Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. *Ann Oncol* 16:279–281
20. Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. *Ann Oncol* 15:1339–1343
21. Kuhn R, Hribaschek A, Eichelmann K et al (2002) Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. *Invest New Drugs* 20:351–356
22. McWilliams RR, Foster NR, Quevedo FJ et al (2007) NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results. *J Clin Oncol, Proc Am Soc Clin Oncol* 25:217s (abstr 4578)
23. Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. *Jpn J Cancer Res (Gann)* 69:763–772
24. Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH (1996) Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. *Anticancer Drugs* 7:728–733
25. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. *Jpn J Clin Oncol* 36:552–556
26. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. *Cancer Chemother Pharmacol* 62(5):849–855
27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205–216
28. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. *Br J Cancer* 96:896–902
29. Furuse J, Takada T, Miyazaki M et al (2008) Guidelines for chemotherapy of biliary tract and ampullary carcinomas. *J Hepatobiliary Pancreat Surg* 15:55–62
30. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. *Jpn J Clin Oncol* 37:843–851

The Usefulness of Perfusion-Weighted Magnetic Resonance Imaging in Advanced Pancreatic Cancer

Makoto Ueno, MD,* Tetsu Niwa, MD,† Shinichi Ohkawa, MD,* Ayumi Amano, MD,*
Takahiro Masaki, MD,* Kaoru Miyakawa, MD,* and Tetsuo Yoshida, MD†

Objectives: Perfusion-weighted magnetic resonance imaging (MRI) can detect the changes of signal intensity in tumors. We evaluated the prognostic value of perfusion-weighted MRI in patients with advanced pancreatic cancer (PC).

Methods: Perfusion-weighted MRI was performed before treatment on 27 consecutive patients with advanced PC. The American Joint Committee on Cancer (AJCC) stages of patients were as follows (8, stage III; 19, stage IV). Imaging acquisition was continually repeated with echo planar sequence every 2 seconds for 2 minutes after a bolus injection of gadolinium. We made a time intensity curve of PC and calculated the signal ratio (SR) on perfusion-weighted imaging. We assessed the relation between SR and clinical factors including tumor stage, lymph node metastasis, liver metastasis, and so on. Patients were divided into low and high SR group and compared SR with the overall survival.

Results: All cases showed transient decreases signal intensity (SR, 6.9–55.7%). These patients were classified into 2 groups at cutoff median SR of 22.0%. The high SR group significantly correlated with the higher stage ($P = 0.03$) and the presence of lymph node metastasis ($P = 0.04$). The high SR group had significantly shorter overall survival ($P = 0.04$).

Conclusions: Perfusion-weighted MRI may predict the survival in advanced PC patients.

Key Words: MRI, pancreatic cancer, prognosis

Abbreviations: PC - pancreatic cancer, MRI - magnetic resonance imaging, SR - signal ratio, BSA - body surface area, VEGF - vascular endothelial growth factor

(*Pancreas* 2009;38: 644–648)

Pancreatic cancer (PC) has a poor prognosis, and the 5-year survival rate is less than 5%¹ because of the difficulty of early detection and the relative chemoresistance of this tumor. Currently, gemcitabine is the most standard cytotoxic agent.^{1,2} However, the objective response rate of this drug is less than 10%.² Although some clinical trials of systemic chemotherapy that include combinations of gemcitabine have been recently performed, most trials could not show the superiority to gemcitabine.^{3–5} Considering the poor prognosis of advanced PC, it is important to predict the survival of the patients with this cancer.

Recently, perfusion-weighted magnetic resonance imaging (MRI) has been used in the diagnosis of brain and liver

tumors.^{6–10} When a bolus of MR contrast agent passes through the intravascular space, it creates local magnetic susceptibility (T2*) effects which cause a transient signal drop during the first pass of the contrast agent. This negative enhancement is directly proportional to the hemodynamic blood volume map.⁶ To our knowledge, the usefulness of perfusion-weighted MRI in PC has not been evaluated yet. We examined the usefulness of perfusion-weighted MRI in inoperable advanced PC.

MATERIALS AND METHODS

Patients' Characteristics and Follow-Up

Twenty-seven consecutive patients with advanced PC were examined by perfusion-weighted MRI at the Kanagawa Cancer Hospital, Kanagawa, Japan between May 2003 and June 2004 (Table 1). Especially lymph node metastasis was defined as lymph node size over 10 mm on the MR and computed tomography (CT) images. Fully informed consents were obtained from all patients before the examinations. This study was permitted by the independent ethical committee of Kanagawa Cancer Center. The diagnosis was histologically confirmed by examining specimens obtained from 24 cases. If no histological confirmation could be done, the diagnosis was made on the basis of clinical and imaging findings. Metastasis was diagnosed with CT and MRI comprehensively.

MRI Examinations

Magnetic resonance imaging examinations were performed with a 1.5-T superconducting MR system (Excelart XGS; Toshiba Medical System, Tokyo, Japan) in the supine position after an overnight fasting. Before perfusion-weighted MRI, transverse T1-weighted fast gradient echo image (repetition time [TR], 187 ms; echo time [TE], 4 ms) and transverse T2-weighted fast spin echo image (TR, 3150 ms; TE, 10 ms; echo train length, 19) were acquired. The perfusion-weighted MRI was performed by the single-shot gradient echo, echo planar pulse sequence with the following scan parameters: TR, 2000 ms; TE, 45 ms; matrix, 144 × 144; field of view, 30 × 30 cm; slice thickness, 8 mm; inter-slice gap, 1 mm; number of excitations, 1, 13 slices. The acquisition time was 2 seconds. The contrast agent of gadopentetate dimeglumine (Magnevist; Nihon Schering, Osaka, Japan) was automatically injected as a bolus infusion (at a dose of 0.2 mL/kg, 4 mL/s) through a 20-gauge cannula placed in the cubital vein, followed by physiological saline (0.4 mL/kg) to flush the cannula with automated power injector. The patients were asked to hold their breath for 30 minutes. At 30-second intervals, the patient could take a new breath for 5 seconds. The total acquisition time for perfusion-weighted imaging was 2 minutes. Finally, post-contrast transverse T1-weighted fast gradient echo images (TR, 187 ms; TE, 4 ms) were acquired.

Data Analysis

Three regions of interests (ROIs) were placed in APC, and the averaged signal was measured in all dynamic images. All

From the *Hepatobiliary and Pancreatic Medical Oncology Division, and †Radiologic Division, Kanagawa Cancer Center Hospital, Yokohama, Japan. Received for publication August 28, 2008; accepted March 17, 2009.

Reprints: Makoto Ueno, MD, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center Hospital, 1-1-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan (e-mail: uenom@kcch.jp).

This work was supported by the Fund for Cancer Research from Kanagawa Prefecture.

The results of this work were presented in part at ASCO, Orlando (abstract #4109) in 2005.

Copyright © 2009 by Lippincott Williams & Wilkins

TABLE 1. Categorical Distributions of the Baseline Characteristics in All Patients

Age, y		63 ± 8.9
Males/females		16/11
CA19-9 change >20% decrease, ≤20% decrease		20/7
Tumor stage III/IV		8/19
Tumor location (head/body-tail)		7/20
Median tumor diameter (mm)		40
Primary tumor	T3/T4	11/16
Lymph nodes	N0/N1	23/4
Distant metastasis liver: lymph nodes: peritoneum: others		11: 4: 3: 3
Chemotherapy		
Gemcitabine		20
S-1		3
Gemcitabine + S-1		4

the ROI measurements were done on the workstation. Dynamic perfusion images as well as CT scans, pre- and post-contrast T1-weighted images, and T2-weighted images were referred for tumor location and extent. The vessels and cystic areas were avoided with reference to the T1-weighted, T2-

weighted, and post-contrast T1-weighted images for signal intensity measurement.

The ROI placement and size of the ROI were chosen precisely for each lesion so as to use the maximum ROI without volume averaging. To ensure that the same areas were measured, ROI was copied and pasted onto each dynamic image. When ROI was not the same portion of the tumor in the dynamic images with the patients' breathing, ROI was carefully moved manually so as to measure the signal at the same portion of the tumor in the dynamic images. All the ROI measurements were performed with 1 experienced radiologist who had no background about the clinical data.

We calculated the signal ratio (SR) using a time-intensity curve. The formula of SR is as follows: $SR = (\text{unenhanced signal intensity} - \text{maximal enhanced signal intensity}) / \text{unenhanced signal intensity}$. We classified the patients into 2 groups according to the median SR as follows: high SR, low SR (Figs. 1, 2).

Chemotherapeutic Regimens

Most patients were treated with gemcitabine and the remains with S-1, or a combination of both as clinical trials. Twenty patients received chemotherapy with gemcitabine (1000 mg/m^2), which was administered once weekly for 3 weeks followed by 1 week of rest. Three patients were treated with S-1 ($80\text{--}120 \text{ mg/body}$), which was given twice daily for 28 days followed by 2 weeks of rest. Based on previous studies,¹¹ the body surface area (BSA) was used to determine the dose of S-1




FIGURE 1. Perfusion-weighted MRI (with negative enhancement) showing high SR in a 63-year-old women with advanced pancreatic body cancer. A, T1-weighted fast gradient echo image (187/4). B, T2-weighted fast spin echo image (3150/10). C, perfusion-weighted MR pre-contrast image. D, the time intensity curve of SR. These MR images show an irregular tumor in the pancreatic body (A, B, C, arrows). The time intensity curve (D) shows a large signal drop. The SR was 33%.




FIGURE 2. Perfusion-weighted MRI (with negative enhancement) showing low SR in a 68-year-old man with advanced pancreatic body cancer. A, T1-weighted fast gradient echo image (187/4). B, T2-weighted fast spin echo image (3150/10). C, perfusion-weighted MR pre-contrast image. D, the time intensity curve of SR. These MR images show an irregular tumor in the pancreatic body (A, B, C, arrows). The time intensity curve (D) shows a small signal drop. The SR was 12%.

as follows; BSA less than 1.25 m², 80 mg; BSA 1.25 to 1.5 m², 100 mg; BSA greater than 1.5 m², 120 mg. The remaining 4 patients received combination chemotherapy with gemcitabine (400–1000 mg/m²) and S-1 (40–100 mg/body) conducted as a phase I trial at our hospital. Dose escalation was performed in a stepwise manner in which the dose of 1 drug was escalated, whereas the dose of the other drug was kept constant. Chemotherapy was continued until disease progression, death, or unacceptable toxicity.

Statistical Analysis

The relations between SR and clinical factors were assessed using Fisher exact test. The examined factors were as follows: sex, age (median of 63 years), AJCC stage (III and IV), primary tumor (T3, T4), tumor location (head/body-tail), tumor diameter, lymph node metastasis, liver metastasis, CA19-9 response (divided at cutoff value of 20% decrease after the first cycle of chemotherapy), and chemotherapy (gemcitabine, others).

Survival curves were plotted according to Kaplan-Meier. The continuous SR values were divided according to cutoff value (median). The age and tumor diameter were divided at cutoff value (mean). Differences in the overall survival were calculated with the log-rank test. The overall survival was measured from the first day of chemotherapy to the date of death. Two-sided $P < 0.05$ were considered as statistically significant. All computations were performed using the Statis-

tical Package for Social Sciences (version 11.0; SPSS Inc, Chicago, Ill).

RESULTS

Patients' Characteristics

The patients' characteristics were as follows: sex, 16 men and 11 women; age, ranged from 43 to 79 years with a median of 63 years; tumor stage (III/IV), 8/19; primary tumor (T3/ T4), 11/16; tumor location (head/ body-tail), 7/20. The median tumor diameter was 40 mm. Lymph node metastases were recognized in 4 patients (in the regional lymph nodes and around the abdominal aorta). Liver metastases were recognized in 11 patients. Other distant metastases were detected in the peritoneum, 3; ovary, 1; and bone, 2 (Table 1).

Quantitative Analysis of Signal Intensity by Perfusion-Weighted MRI

We noticed MRI signal change of tumor intensity in all patients. The mean size of ROIs was 199 ± 73 mm². None of the patients experienced complications such as allergic reactions or renal dysfunctions to the contrast agent. Signal ratios ranged from 6.9% to 55.7% (median = 22.0%). The patients were classified to high/low SR groups according to their SRs greater/ less than median value. The high SR group was consisted of 13 patients, whereas the low SR group was consisted of 14 patients (Figs. 1, 2).

TABLE 2. Relation Between Perfusion MRI SR and Various Factors

Variable	Class	SR < 22.0	SR ≥ 22.0	P
Sex	Male	9	6	0.45
	Female	5	7	
Age, y	≤63*	7	7	1.00
	>63*	7	6	
Tumor stage	III	7	1	0.03†
	IV	7	12	
Primary tumor	T3	4	7	0.07
	T4	10	6	
Tumor location (head/body-tail)	Head	6	1	0.07
	Body-tail	8	12	
Tumor diameter (mm)	≤40	7	6	1.00
	>40	7	7	
Lymph node metastasis	Positive	0	4	0.04†
	Negative	14	9	
Liver metastasis	Positive	3	8	0.054
	Negative	11	5	
CA19-9 change	>20% decrease	6	2	0.21
	≤20% decrease	8	11	
Chemotherapy	Gemcitabine	11	8	0.42
	Others	3	5	

*Median value.

†Statistically significant.

The Relation Between SR and Clinical Factors

The high SR group significantly correlated with the higher stage ($P = 0.03$) and the presence of lymph node metastasis ($P = 0.04$) (Table 2).

Patients' Survival

The overall survival ranged from 38 to 612 days with a median of 217 days. The median overall survival was 130 days in the high SR group and 262 days in the low SR group. The high SR group had a shorter overall survival than the low SR group as calculated with the log-rank test ($P = 0.04$; Fig. 3).

DISCUSSION

In perfusion-weighted MRI, gadolinium, an extracellular compartment contrast agent, initially enters the intravascular space and then rapidly distributes into the extracellular space. This paramagnetic contrast agent enters the intravascular space by bolus injection and generates a drop in the signal intensity with perfusion-weighted imaging. After the first pass, it distributes rapidly into the extracellular component and the signal intensity rises.⁷

Perfusion-weighted MRI has been widely used in neuroimaging diagnosis.¹² In case of abdominal imaging, this technique has been applied for liver tumors where the degree of tumor perfusion correlated with the vascularity in angiography, and accordingly, it is useful to evaluate the effectiveness of transarterial chemoembolization.⁷ To our knowledge, this is the first report about the perfusion-weighted MRI of the PC.

In this study, higher SRs on perfusion-weighted MRI correlated with the tumor stage and lymph node metastasis. High SR indicated poor prognosis. Recently, it has been reported that perfusion-weighted MRI correlated with the expression of the

vascular endothelial growth factor (VEGF) in various cancers.¹³ And in the PC, the expression of VEGF is reportedly associated with poor prognosis.^{14,15} In this regard, the signal changes of perfusion-weighted MRI may also correlate with the VEGF expression in the PC.

It has been reported that the survival was longer for the patients having avascular tumors as compared with those having vascular tumors on the contrast-enhanced ultrasonography.¹⁶ Ohshima et al¹⁷ investigated the relation between contrast-enhanced Doppler signals and the VEGF expression in PCs and reported that the VEGF expression was significantly higher in the vascular tumors than in the avascular tumors. Our results support these studies. However, we could not compare the histology with perfusion-weighted MRI because the biopsy specimens were small, and this study was performed on inoperable patients. Further investigation on operable patients will be needed for validation in the future.

Several prognostic factors have been reported. Ikeda et al¹⁸ reported that the performance status of 0–1 ($P < 0.01$), absence of regional lymph node metastasis ($P < 0.01$), and serum CA 19-9 level of less than 1000 ($P = 0.02$) were independent favorable prognostic factors. Furthermore, the histologic grade and tumor stage are reportedly prognostic factors of PC.^{19,20} Considering these reports, the correlation of SRs on perfusion-weighted MRI with lymph node metastasis and tumor stage may support the possibility of using perfusion-weighted MRI as a prognostic factor. However, our study has several limitations. Although high SR patients had poor prognosis, our study was preliminary, and the subjects were few. Therefore, prognostic factors including SR and clinical factors should be examined on more patients.

In the imaging study, we diagnosed PC from the surrounding tissues and normal parenchyma and detected lymph node metastasis, liver metastasis, and other metastasis using mainly MRI and CT comprehensively. As a limitation of MRI, tumors less than 1 cm in size cannot be reliably detected because of poor spatial resolution, and huge tumors (>15 cm) cannot be imaged simultaneously. However, most tumors were between these sizes. Furthermore, the signal-to-noise ratio of echo planar imaging was relatively low in the current MR scanners. Yet, we




FIGURE 3. Survival curves comparing the high and low SR groups in advanced PC. Based on the Kaplan-Meier method and the log-rank test, the high SR group (solid line) had a shorter overall survival than the low SR group (dotted line) ($P = 0.04$).

could detect the changes of signal intensity in all cases in this study and make a time intensity curve.

Regarding ROIs, 3 ROIs were placed in APC, and the vessels and cystic areas were avoided with reference to the T1-weighted, T2-weighted, and post-contrast T1-weighted images for signal intensity measurement. Nonetheless, it was impossible to avoid the desmoplastic change and edema perfectly. Although it may be more reproducible to include the entire tumor within the ROI, we considered that this method was not accurate because of the unclear tumor margins and the possibility of including the tumor margin vessels. Moreover, the PCs on MRI move with the patients' breathing. We located ROIs carefully and manually so as to measure the same position on all dynamic images in this study.

Regarding the parameters, we investigated only SR as a preliminary study because the target lesions move with breathing. In the future, motion correction should be performed to allow calculation of parameters such as blood flow, blood volume, mean transit time using K-trans model. The pre- and post-chemotherapy perfusion changes should also be assessed.

In conclusion, we suggest that perfusion-weighted MRI may predict the survival in the APC patients, although this study is preliminary and further investigations on large groups are needed in the future.

REFERENCES

1. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. *Ann Oncol.* 1996;7:347-353.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol.* 1997;15:2403-2413.
3. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. *Br J Cancer.* 2006;95:587-592.
4. Heinemann V, Quetzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol.* 2006;24:3946-3952.
5. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. *J Clin Oncol.* 2006;24:4441-4447.
6. Chan JH, Tsui EY, Luk SH, et al. Detection of hepatic tumor perfusion following transcatheter arterial chemoembolization with dynamic susceptibility contrast-enhanced echoplanar imaging. *Clin Imaging.* 1999;23:190-194.
7. Tsui EY, Chan JH, Cheung YK, et al. Evaluation of therapeutic effectiveness of transarterial chemoembolization for hepatocellular carcinoma: correlation of dynamic susceptibility contrast-enhanced echoplanar imaging and hepatic angiography. *Clin Imaging.* 2000;24:210-216.
8. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. *Radiology.* 1990;176:211-220.
9. Nighoghossian N, Berthezene Y, Meyer R, et al. Assessment of cerebrovascular reactivity by dynamic susceptibility contrast-enhanced MR imaging. *J Neurol Sci.* 1997;149:171-176.
10. Fujioka S, Yoshida K, Yanagisawa S, et al. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. *Cancer.* 2001;92:1788-1797.
11. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. *Br J Cancer.* 2000;83:141-145.
12. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. *Radiology.* 2002;223:11-29.
13. Ikeda O, Nishimura R, Miyayama H, et al. Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. *Acta Radiol.* 2004;45:446-452.
14. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. *Br J Cancer.* 1999;79:1553-1563.
15. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. *Cancer.* 2000;88:2239-2245.
16. Masaki T, Ohkawa S, Amano A, et al. Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. *Cancer.* 2005;103:1026-1035.
17. Ohshima T, Yamaguchi T, Ishihara T, et al. Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. *Pancreas.* 2004;28:335-343.
18. Ikeda M, Okada S, Tokuyue K, et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. *Cancer.* 2001;91:490-495.
19. Bakkevold KE, Kambestad B. Staging of carcinoma of the pancreas and ampulla of Vater. Tumor (T), lymph node (N), and distant metastasis (M) as prognostic factors. *Int J Pancreatol.* 1995;17:249-259.
20. Bottger T, Zech J, Weber W, et al. Relevant factors in the prognosis of ductal pancreatic carcinoma. *Acta Chir Scand.* 1990;156:781-788.

Ruptured pseudoaneurysm of the splenic artery complicating endoscopic ultrasound-guided fine-needle aspiration biopsy for pancreatic cancer

Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a safe procedure, although major complications do rarely occur. Pseudoaneurysm rupture is an emergency that can cause life-threatening hemorrhage. An exceedingly rare case of ruptured pseudoaneurysm of the splenic artery following EUS-FNA is described.

A 62-year-old man was referred for investigation of a pancreatic tumor. On abdominal computed tomography (CT), a low-density area was seen running from the pancreatic body, involving the celiac and splenic arteries (● Fig. 1). Angiography showed encasement of the splenic artery (● Fig. 2). Therefore, EUS-FNA was performed with two separate passes into the lesion using a 22-gauge needle. Cytological analysis showed a pancreatic adenocarcinoma. Nineteen days later abdominal CT showed a pseudocyst in the pancreatic body and tail (● Fig. 3), and 30 days later (i.e., 30 days after EUS-FNA) the patient developed hematemesis and hemorrhagic shock. Upper gastrointestinal endoscopy showed a hemorrhagic gastric ulcer in the posterior wall of the middle body (● Fig. 4). Since endoscopic treatment was unsuccessful, angiography was performed and showed a pseudoaneurysm of the splenic artery. Coil embolization was performed in and around the pseudoaneurysm. After 7 days the pancreatic pseudocyst had narrowed (● Fig. 5); there was no further recurrence.

The overall complication rate of EUS-FNA is 1%–2% [1]. The major complications are postaspiration infection in cystic lesions, bleeding, pancreatitis, and cervical and duodenal perforation [2]. Three different mechanisms are recognized as causing pseudoaneurysm formation [3], but all are called pseudoaneurysm because the end result is a cystic vascular structure surrounded by a fibrous wall. Pseudoaneurysms can rupture into the peritoneal cavity, retroperitoneum, gastrointestinal tract, biliary tract, and pancreatic duct. The most common vessel involved is the splenic artery as it runs along the pancreatic bed before reaching the spleen [4]. To our knowledge, this is the




Fig. 1 On abdominal CT, a low-density area was seen running from the pancreatic body, involving the celiac and splenic arteries.




Fig. 2 Angiography showed encasement of the splenic artery.




Fig. 3 Abdominal CT 19 days later showed a pseudocyst in the pancreatic body and tail.




Fig. 4 Upper gastrointestinal endoscopy showed a hemorrhagic gastric ulcer in the posterior wall of the middle body.




Fig. 5 Coil embolization in and around the pseudoaneurysm was performed, and 7 days later the pancreatic pseudocyst had narrowed.

first case report of a ruptured pseudoaneurysm of the splenic artery complicating EUS-FNA.

Endoscopy_UCTN_Code_CPL_1AL_2AD

K. Matsumoto¹, K. Hara¹, A. Sawaki¹, N. Mizuno¹, S. Hijioka¹, H. Imamura¹, Y. Niwa², M. Tajika², H. Kawai², S. Kondo², Y. Inaba³, K. Yamao¹

- ¹ Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
- ² Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
- ³ Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan

References

- 1 *Bhutani MS.* Endoscopic ultrasound guided fine needle aspiration of pancreas. In: *Bhutani MS (ed).* Interventional endoscopic ultrasonography. Amsterdam: Harwood Academic, 1999: 65–72
- 2 *O’Toole D, Palazzo L, Arotcarena R et al.* Assessment of complications of EUS-guided fine-needle aspiration. *Gastrointest Endosc* 2001; 53: 470–474
- 3 *Hsu JT, Yeh CN, Hung CF et al.* Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. *BMC Gastroenterol* 2006; 6: 3
- 4 *Tessier DJ, Stone WM, Fowl RJ et al.* Clinical features and management of splenic artery pseudoaneurysm: case series and cumulative review of literature. *J Vasc Surg* 2003; 38: 969–974

Bibliography

DOI 10.1055/s-0029-1215323
Endoscopy 2010; 42: E27–E28
 © Georg Thieme Verlag KG Stuttgart · New York ·
 ISSN 0013-726X

Corresponding author

K. Yamao, MD
 Department of Gastroenterology
 Aichi Cancer Center Hospital
 1-1 Kanokoden
 Chikusa-ku
 Nagoya 464-8681
 Japan
 Fax: +81-52-7642942
 kyamao@aichi-cc.jp

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma

Reiko Takayama · Hidewaki Nakagawa · Akira Sawaki · Nobumasa Mizuno · Hiroki Kawai · Masahiro Tajika · Yasushi Yatabe · Keitaro Matsuo · Rie Uehara · Ken-ichiro Ono · Yusuke Nakamura · Kenji Yamao

Received: 25 November 2008 / Accepted: 30 June 2009 / Published online: 30 September 2009
© Springer 2009

Abstract

Background and Aims Serum biomarkers for the early detection of pancreatic cancer are not currently available. We evaluated the usefulness of a novel serum marker, REG4, in the diagnosis of pancreatic cancer, as compared to carbohydrate antigen (CA) 19-9.

Electronic supplementary material The online version of this article (doi:10.1007/s00535-009-0114-y) contains supplementary material, which is available to authorized users.

R. Takayama · A. Sawaki · N. Mizuno · K. Yamao (✉)
Department of Gastroenterology, Aichi Cancer Center Hospital,
1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-0021, Japan
e-mail: kyamao@aichi-cc.jp

H. Kawai · M. Tajika
Department of Endoscopy, Aichi Cancer Center Hospital,
Nagoya, Japan

Y. Yatabe
Department of Pathology and Molecular Diagnosis,
Aichi Cancer Center Hospital, Nagoya, Japan

K. Matsuo
Division of Epidemiology and Prevention,
Aichi Cancer Center Hospital, Nagoya, Japan

H. Nakagawa · Y. Nakamura
Laboratory of Molecular Medicine, Human Genome Center,
Institute of Medical Science, The University of Tokyo,
Tokyo, Japan

R. Uehara · K. Ono
Medical and Biological Laboratories Co., LTD, Nagoya, Japan

R. Takayama
Department of Gastroenterology, Matsusaka Central Hospital,
Matsusaka, Japan

Methods We collected pretherapeutic sera from 92 patients with pancreatic cancer, as well as sera from 28 patients with other pancreatic tumors, 11 patients with pancreatitis, and 69 healthy controls. Serum levels of REG4 were measured using a standard sandwich enzyme-linked immunosorbent assay (ELISA).

Results Compared with healthy controls, serum levels of REG4 were higher in pancreatic cancer patients ($P < 0.001$), and in patients with pancreatitis ($P < 0.001$). Receiver operating characteristic (ROC) analysis indicated that serum REG4 performed better than serum CA19-9 for distinguishing patients with pancreatic cancer from healthy controls [areas under the curve (AUC) for REG4 and CA19-9 were 0.922 and 0.884, respectively]. When we validated the study, the sensitivity of REG4 for pancreatic cancer was 94.9%, specificity was 64.0%, and accuracy was 77.5% for the REG4 cutoff value of 3.49 ng/ml. No correlation was seen between serum REG4 and CA19-9 levels, with the sensitivity, specificity, and accuracy of the combined markers reaching 100.0, 60.0, and 77.5%, respectively. No significant differences were seen among any stages of pancreatic cancer. In surgical specimens, immunohistochemical analysis found a correlation between serum REG4 levels and REG4 expression in pancreatic cancers.

Conclusions REG4 is expressed in pancreatic cancer, and serum levels of REG4 offer a useful indicator for distinguishing between patients with pancreatic cancer and healthy subjects. Serum REG4 has potential for use as a screening serum marker for pancreatic cancers, including early-stage cancers.

Keywords REG4 · Serum tumor antigen · Biomarker · Pancreatic cancer

Introduction

Pancreatic cancer is the fourth leading cause of cancer-related deaths in Western countries and shows the worst mortality among common malignancies, with a 5-year survival rate of only 5% [1, 2]. Estimates from 2007 predicted 37170 newly diagnosed cases of pancreatic cancer, and noted that a roughly equal number of deaths would be attributed to pancreatic cancer in the United States [3]. The majority of pancreatic cancer patients are diagnosed at an advanced stage, at which point effective therapies are no longer available. At present, surgical resection is the only possibility for a cure, but 80–90% of patients who undergo curative surgery suffer relapses and die from metastatic or disseminated disease [4]. Some approaches utilize a combination of surgery with chemotherapy based on gemcitabine or 5-fluorouracil (5-FU), with or without radiotherapy, and such modalities have been shown to improve the quality of life in these patients [5]. However, such treatments for advanced or relapsed pancreatic cancer generally have very limited effect with regard to improvement of long-term survival, since pancreatic cancers are extremely biologically aggressive and they are usually chemotherapy- and radiation-resistant [5]. The National Cancer Institute Pancreatic Cancer Progress Review Group has found that only about 4% of diagnosed patients live for more than 5 years [6]. However, in the early stages of pancreatic cancer, prognosis is relatively hopeful, with the 5-year survival of patients with stage I tumors less than 2 cm in size and no metastasis being seen to reach more than 50% [7]. One of the most realistic strategies for dealing with this lethal disease is, thus, screening for the early stages, to enable patients to undergo margin-negative surgical resections and thus achieve a potential for cure [8].

However, early-stage pancreatic cancer is extremely difficult to diagnose, comprising less than 10% of newly diagnosed pancreatic cancers. The reason for this is that patients with early-stage pancreatic cancer are usually asymptomatic, and optimal imaging or diagnosis of small pancreatic lesions requires specialized and invasive skills, despite the rapid progress that has been made in improving imaging techniques [8]. Many investigators and clinicians have therefore sought to find accurate and sensitive non-invasive serum markers of pancreatic cancer. In addition, screening methods for early pancreatic cancer involve examining high-risk populations who smoke, have alcohol consumption-associated chronic pancreatitis, have a recent onset of diabetes, and have a family history of pancreatic cancer [9].

Carbohydrate antigen (CA) 19-9 is currently the most widely used serum marker available. However, American Society of Clinical Oncology (ASCO) 2006 guidelines for the use of tumor markers do not recommend CA19-9 as a

screening test for pancreatic cancer. The reason for this is that CA19-9 is not specific for pancreatic cancer and is also elevated in many other gastrointestinal tumors and in inflammatory or benign conditions of the hepatobiliary system. Thus, CA19-9 may not be elevated in small malignant tumors of the pancreas [10]. Establishment of screening strategies through the development of novel serum markers that are more specific and more sensitive to pancreatic cancer is thus urgently needed.

To identify target molecules for diagnosis and therapy of pancreatic cancer, in earlier experiments, we generated precise genome-wide gene expression profiles of pancreatic cancer cells by combining our genome-wide cDNA microarrays with laser beam microdissection [11]. Among the numerous *trans*-activated genes found in pancreatic cancer cells, we focused on a recently discovered member of the regenerating islet-derived (REG) family as a tumor marker of pancreatic cancer, REG4 [12]. The REG family comprises secreted proteins that are speculated to play a role in tissue regeneration and inflammation in digestive organs [13–15]. Expressions of members of the REG family have been reported to be upregulated in several gastrointestinal cancers and to function as trophic or anti-apoptotic factors in cancers [15, 16]. Our previous study validated the overexpression of REG4 in pancreatic cancer cells through an immunohistochemical analysis that used anti-REG4 antibody. We were able to detect REG4 in a small set of pancreatic cancer sera when using an enzyme-linked immunosorbent assay (ELISA), suggesting potential for REG4 use as a serum marker for pancreatic cancers.

The previous study also established an ELISA system that was able to detect serum REG4 more sensitively. Subsequently, we were able to coordinate a large clinical study using this REG4 ELISA method to evaluate whether serum REG4 detection could be used as a diagnostic marker for pancreatic cancer [12].

Patients, materials, and methods

Clinical samples

We selected a population of 120 patients with pancreatic tumors, including ductal adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, acinar cell adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), endocrine tumor, mucinous cystic neoplasm (MCN), serous cystic neoplasm (SCN), and solid pseudopapillary tumor (SPT), along with 11 patients with pancreatitis and 69 healthy controls. We categorized ductal adenocarcinoma, adenosquamous carcinoma, anaplastic carcinoma, invasive carcinoma derived from intraductal tumor, and intraductal papillary mucinous carcinoma (IPMC) as pancreatic